Compass Pathways Launches Change the Tune in TRD
LONDON and NEW YORK — September 15, 2026 Compass Pathways plc announced the launch of Change the Tune in...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONDON and NEW YORK — September 15, 2026 Compass Pathways plc announced the launch of Change the Tune in...
LONDON and NEW YORK — September 10, 2026 Compass Pathways plc announced that five organizations have been awarded grants...
LONDON and NEW YORK — September 9, 2026 Compass Pathways plc announced positive topline 52-week open-label results from Part...
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
WASHINGTON, D.C., April 24, 2026 The U.S. Food and Drug Administration has announced a series of accelerated regulatory actions...
